Article
Biochemistry & Molecular Biology
Shinri Sato, Eisuke Shimizu, Jingliang He, Mamoru Ogawa, Kazuki Asai, Hiroyuki Yazu, Robert Rusch, Mio Yamane, Fan Yang, Shinji Fukuda, Yutaka Kawakami, Kazuo Tsubota, Yoko Ogawa
Summary: In this study, it was found in a mouse model that gentamicin (GM) significantly suppressed systemic cGVHD phenotypes and ocular manifestations, and reduced inflammatory cell infiltration and fibrosis in cGVHD-targeted organs. Although GM maintained higher levels of regulatory T cells, there were fewer Th17 cells and IL-6-producing macrophages in cGVHD-targeted organs. These findings suggest that orally administered GM may have positive effects in a cGVHD mouse model.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Ori Bar, Sharon Elad, Batia Avni, Jawad Abu-Tair, Bianca Zaharia, Aiham Hanut, Yehuda Zadik
Summary: This study presented new cases of oral VX in chronic graft-versus-host disease (cGVHD) and reviewed relevant literature, identifying 12 patients with OVX. Most patients had oral mucosal lichenoid lesions, but not in close proximity to the VX lesion. It is recommended that clinicians be familiar with the clinical and histological features of OVX to consider it in the differential diagnosis of oral lesions in cGVHD patients.
SUPPORTIVE CARE IN CANCER
(2021)
Review
Immunology
Victor Tollemar, Karin Legert, Rachael V. V. Sugars
Summary: Chronic Graft-versus-Host Disease (cGVHD) is a common complication after allogenic hematopoietic cell transplantation (HCT). It frequently affects the mouth and can be diagnosed by mucosal lichenoid lesions, salivary gland dysfunction, and limited oral aperture. The pathophysiology of oral cGVHD involves acute and chronic inflammation, dysregulated immunity, and fibrotic healing, which may lead to increased malignant transformation rate.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Juliette Stolze, Marlou Boor, Mette D. Hazenberg, Henk S. Brand, Judith E. Raber-Durlacher, Alexa M. G. A. Laheij
Summary: The study assessed the impact of oral chronic graft-versus-host-disease (cGVHD) symptoms on oral health-related quality of life (OHRQoL). Results showed that OHRQoL was mainly negatively affected by oral pain and sensitivity, rather than the severity of oral mucosal cGVHD. Special attention from healthcare professionals is essential to improve OHRQoL for patients with oral cGVHD.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Oncology
Joel B. Epstein, Judith E. Raber-Durlacher, Geena L. Epstein, Mette D. Hazenberg, Dimitrios Tzachanis, Ricardo T. Spielberger
Summary: This study provides long-term follow-up of patients with chronic symptomatic oral chronic graft-versus-host-disease (cGVHD) managed with photobiomodulation therapy (PBM therapy. The results show that PBM therapy is effective in controlling oral sensitivity and mucosal changes in cGVHD, with treatment frequency individualized for optimal control of symptoms and signs.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Oncology
Ori Finfter, Batia Avni, Sigal Grisariu, Yaron Haviv, Chen Nadler, Ori Rimon, Yehuda Zadik
Summary: Photobiomodulation therapy (PBMt) appears to be a promising treatment for refractory oral cGVHD lesions, providing rapid pain relief with relatively long-lasting effects. In this study, most patients reported a significant reduction in pain levels after treatment, with no adverse effects reported.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Dentistry, Oral Surgery & Medicine
Martina Kaurinovic, Konstantina Delli, Ana-Mae E. Jonk, Anouschka Biswana, Carin L. E. Hazenberg, Goda Choi, Marco R. de Groot, Linde M. Morsink, Arjan Vissink, Mar Bellido
Summary: The study aimed to assess the effect of ruxolitinib on the oral mucosa of SR-cGVHD patients with oral involvement. In an observational longitudinal patient study, 53 patients with SR-cGVHD and oral involvement were treated with ruxolitinib. The baseline condition of the oral mucosa was compared to its condition at 4 and 12 weeks after starting ruxolitinib.
CLINICAL ORAL INVESTIGATIONS
(2022)
Review
Immunology
Fathima A. Mohamed, Govindarajan Thangavelu, Stephanie Y. Rhee, Peter T. Sage, Roddy S. O'Connor, Jeffrey C. Rathmell, Bruce R. Blazar
Summary: The therapeutic efficacy of allo-HSCT is limited by the development of GVHD, with immune dysregulation leading to expansion of alloreactive cells and reduction in regulatory cells. New therapies are needed to restore the balance between effector and regulatory immune cells while preserving the beneficial graft-versus-tumor effect.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Hematology
Noa G. Holtzman, Steven Z. Pavletic
Summary: Chronic graft-versus-host disease (cGVHD) is a systemic complication of allogeneic haematopoietic stem cell transplantation that can lead to increased morbidity and mortality. Despite limited curative treatment options, recent collaborative research efforts have led to discovery of new second-line therapies. Comprehensive and sustained multidisciplinary efforts are crucial for successful management of cGVHD.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Chemistry, Medicinal
Andrey Kozlov, Maria Estrina, Olesia Paina, Tatiana Bykova, Anna Osipova, Polina Kozhokar, Zhemal Rakhmanova, Irina Solodova, Elena Morozova, Alexander Alyansky, Irina Kulagina, Asmik Gevorgian, Anna Dotsenko, Ivan Moiseev, Alexey Chukhlovin, Alexander Kulagin, Sergey Bondarenko, Elena Semenova, Ludmila Zubarovskaya
Summary: This study investigated the efficacy and safety of extracorporeal photopheresis (ECP) in children with chronic graft versus host disease (cGVHD). The results showed that a portion of patients responded partially or completely to ECP treatment, with a certain survival rate within 5 years.
Article
Multidisciplinary Sciences
Giselle Rocha Pinto, Viviane Almeida Sarmento, Paulo Cirino De Carvalho-Filho, Vitor Antonio Fortuna, Ryan dos Santos Costa, Rogerio Reis Conceicao, Soraya Castro Trindade
Summary: This case series observational study aims to evaluate the participation of cytokines, chemokines, transcription factors, and heat shock proteins in the pathogenesis of oral graft-versus-host disease (oGVHD). The study found that the gene expression levels in the group with oGVHD were mainly up-regulated compared to those without GVHD.
Review
Immunology
Laura Marie Gail, Kimberly Julia Schell, Piotr Lacina, Johanna Strobl, Steven J. Bolton, Emilie Steinbakk Ulriksen, Katarzyna Bogunia-Kubik, Hildegard Greinix, Rachel Emily Crossland, Marit Inngjerdingen, Georg Stary
Summary: Chronic Graft-versus-Host Disease (cGVHD) is a life-threatening inflammatory condition occurring after allogeneic hematopoietic stem cell transplantation. Despite progress in understanding disease pathogenesis, treatment options remain limited. This review provides an overview of the pathogenic and protective mechanisms involving immune subsets, as well as the emerging field of intercellular communication via extracellular vesicles and its implications for cGVHD research. The importance of understanding aberrant cell communication for biomarker discovery and personalized treatment is discussed.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Lydia Verlaat, Katarina Riesner, Martina Kalupa, Beate Jung, Sarah Mertlitz, Constanze Schwarz, Joerg Mengwasser, Claudine Fricke, Olaf Penack
Summary: Despite progress in allo-HCT, cGvHD remains a major hurdle, and improved pre-clinical models are needed. We developed two murine cGvHD models that resemble the clinical manifestations of cGvHD in patients. These models exhibited diverse signs of cGvHD in target organs and decelerated immune cell reconstitution. They can provide a deeper understanding of cGvHD pathology and facilitate the translation of experimental findings into human allo-HCT.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Chao Hong, Rong Jin, Xiaoqiu Dai, Xiaoming Gao
Summary: Chronic graft-versus-host disease (cGVHD) is a common cause of late morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The pathogenesis of cGVHD is complex and involves a variety of immune cells, with antigen presenting cells (APCs) playing crucial roles in presenting antigens to activate pathogenic T cells and mediating the disease through multiple mechanisms. Studies targeting different APCs have shown promising results in treating cGVHD.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Yiwen Liang, Jingyi Shen, Qiu Lan, Kexin Zhang, Yan Xu, Maxwell Duah, Kailin Xu, Bin Pan
Summary: This research found that PD-1 expression on T cells increased in mice with chronic graft-versus-host disease (cGVHD). Intervention of the PD-1/PD-L1 pathway showed a significant impact on the occurrence of cGVHD and graft-versus-tumor effect.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
